-
Mashup Score: 53
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non–Small-Cell Lung Cancer - 30 day(s) ago
MicroabstractOur retrospective study aims to explore the clinical and genomic underpinnings of a durable response to ICI. We identify lower ECOG performance status at diagnosis, the absence of liver metastases at diagnosis and occurrence of irAEs as predictors of a prolonged response. These findings help inform on therapeutic selection and personalized discussions of benefit to patients with lung cancer.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 150
KRAS mutations(m) are the most common oncogenic alterations in NSCLC, occurring in 20–40 % of lung adenocarcinomas [1–3]. While KRAS has been historically considered undruggable, two KRAS G12C inhibitors are now FDA approved [4,5] and there is a suite of emerging KRAS-directed agents in development [6]. Understanding the relative therapeutic benefit of these novel agents, as well as designing clinical trials with prognostic balance between arms, will require a thorough understanding of outcomes and treatment responsiveness of KRASm aNSCLC across subgroups defined by KRASm subtype, PD-L1 status, and comutations.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany - 1 month(s) ago
Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63
CNS metastases occur in 27%-42% of patients with non–small-cell lung cancer (NSCLC) that harbor KRAS G12C mutations at diagnosis. 1 – 4 Prognosis is worse and the incidence of CNS failure is higher in patients with KRAS -mutated NSCLC and CNS metastases, compared with patients without KRAS mutations. 5 – 8 Adagrasib, a KRAS G12C inhibitor, was granted accelerated approval by the US Food and Drug Administration in December 2022 for the treatment of adult patients with KRAS G12C -mutated locally advanced
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 88AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) - 3 month(s) ago
/PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s supplemental New…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71
Immune checkpoint inhibitor (ICI) consolidation following concurrent chemoradiotherapy (CRT) substantially improved PFS and OS in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program - 3 month(s) ago
Kirsten rat sarcoma (KRAS) viral oncogene mutations have been detected in about one third of non-small cell lung cancer (NSCLC) (39% non-squamous vs 4% squamous histology), with p.G12C being the most common pathogenic variant, reported in 12% of overall NSCLC and 39% of KRAS-mutant patients, respectively [1]. Differently from other oncogenic drivers (e.g EGFR, ALK, ROS1), KRASp.G12C mutations are more common in Caucasian and smoker populations [2,3], and are generally characterized by high levels of both programmed death ligand-1 (PD-L1) and tumor mutational burden (TMB) [4].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
Randomized phase 3 KRYSTAL-12 study of adagrasib vs docetaxel in #KRAS G12C NSCLC (post chemo/immunotheraly) meets PFS endpoint. OS pending maturity. Adagrasib has FDA accelerated approval - this is the confirmatory trial. Await data presentation. https://t.co/JHdTNZZoXI